Stephen Goutman, M.D., M.S.

Stephen Goutman, MD, MS is an Assistant Professor in the Department of Neurology and Director of the Pranger Amyotrophic Lateral Sclerosis Clinic and Associate Director of the ALS Center of Excellence at Michigan Medicine. After obtaining a degree in neuroscience at the Johns Hopkins University (Baltimore, MD), Dr. Goutman completed his medical degree at the University of Chicago Pritzker School of Medicine (Chicago, IL) and his neurology residency and neuromuscular fellowship at Cleveland Clinic (Cleveland, OH). He received a Master’s in Clinical Research Design and Statistical Analysis at the University of Michigan (Ann Arbor, MI).

Dr. Goutman evaluates and treats patients with neuromuscular diseases. His area of expertise is amyotrophic lateral sclerosis (ALS)/Lou Gehrig’s Disease where his focus is delivering comprehensive and compassionate care. He is Director of the Pranger ALS Clinic, an ALS Association Certified Center of Excellence http://www.umich-als.org/, where he leads a team of providers that care for persons with ALS and their families. Dr. Goutman is inspired by his patients and thus aims to provide the highest level of care.

Dr. Goutman’s research is focused on identifying causes of and treatments for ALS. He has received funding from National Institutes of Health, the Centers for Disease Control, and The ALS Association with an overall focus of understanding the intersection of genetics and the environment on ALS https://umhealthresearch.org/#studies/HUM00028826. In an article that received widespread attention, Dr. Goutman and colleagues showed a connection between ALS and organochlorine pesticides https://jamanetwork.com/journals/jamaneurology/fullarticle/2519875. Dr. Goutman and colleagues also showed that higher amounts of legacy pollutants associate with a poorer ALS prognosis https://jnnp.bmj.com/content/90/8/907.

Dr. Goutman is a site principal investigator of several multisite clinical trials focused on identifying new ALS treatments and causes and is an active participant with the Northeast ALS Consortium (NEALS) to improve care for ALS. He received a 2016 Young Investigator Award by the World Federation of Neurology Research Group on Motor Neuron Diseases.